vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and SYPRIS SOLUTIONS INC (SYPR). Click either name above to swap in a different company.
SYPRIS SOLUTIONS INC is the larger business by last-quarter revenue ($30.3M vs $18.7M, roughly 1.6× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -12.9%, a 12.1% gap on every dollar of revenue. On growth, SYPRIS SOLUTIONS INC posted the faster year-over-year revenue change (-9.5% vs -25.7%). SYPRIS SOLUTIONS INC produced more free cash flow last quarter ($-1.5M vs $-15.8M). Over the past eight quarters, SYPRIS SOLUTIONS INC's revenue compounded faster (-7.7% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Sypris Solutions Inc. is a U.S.-headquartered provider of highly engineered components and specialized technical services, primarily serving aerospace, defense, automotive and commercial industrial markets. It delivers custom manufacturing, performance testing, and value-added engineering support for mission-critical systems and parts for global enterprise clients.
CTMX vs SYPR — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $30.3M |
| Net Profit | $-154.0K | $-3.9M |
| Gross Margin | — | 4.6% |
| Operating Margin | -6.9% | -10.9% |
| Net Margin | -0.8% | -12.9% |
| Revenue YoY | -25.7% | -9.5% |
| Net Profit YoY | 97.6% | -2992.6% |
| EPS (diluted) | — | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $30.3M | ||
| Q3 25 | — | $28.7M | ||
| Q2 25 | $18.7M | $31.4M | ||
| Q1 25 | $50.9M | $29.5M | ||
| Q4 24 | $38.1M | $33.4M | ||
| Q3 24 | $33.4M | $35.7M | ||
| Q2 24 | $25.1M | $35.5M | ||
| Q1 24 | $41.5M | $35.6M |
| Q4 25 | — | $-3.9M | ||
| Q3 25 | — | $517.0K | ||
| Q2 25 | $-154.0K | $-2.1M | ||
| Q1 25 | $23.5M | $-899.0K | ||
| Q4 24 | $18.9M | $135.0K | ||
| Q3 24 | $5.7M | $390.0K | ||
| Q2 24 | $-6.5M | $16.0K | ||
| Q1 24 | $13.8M | $-2.2M |
| Q4 25 | — | 4.6% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | — | 8.2% | ||
| Q1 25 | — | 11.4% | ||
| Q4 24 | — | 16.1% | ||
| Q3 24 | — | 16.8% | ||
| Q2 24 | — | 15.9% | ||
| Q1 24 | — | 8.1% |
| Q4 25 | — | -10.9% | ||
| Q3 25 | — | -6.1% | ||
| Q2 25 | -6.9% | -4.6% | ||
| Q1 25 | 44.4% | -0.4% | ||
| Q4 24 | 46.4% | 3.9% | ||
| Q3 24 | 12.3% | 4.8% | ||
| Q2 24 | -33.7% | 3.6% | ||
| Q1 24 | 28.1% | -3.9% |
| Q4 25 | — | -12.9% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | -0.8% | -6.5% | ||
| Q1 25 | 46.2% | -3.0% | ||
| Q4 24 | 49.6% | 0.4% | ||
| Q3 24 | 17.2% | 1.1% | ||
| Q2 24 | -26.0% | 0.0% | ||
| Q1 24 | 33.3% | -6.2% |
| Q4 25 | — | $-0.17 | ||
| Q3 25 | — | $0.02 | ||
| Q2 25 | — | $-0.09 | ||
| Q1 25 | — | $-0.04 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | — | $0.02 | ||
| Q2 24 | — | $0.00 | ||
| Q1 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $17.8M |
| Total Assets | $175.1M | $107.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $17.8M | ||
| Q3 25 | — | $20.0M | ||
| Q2 25 | $119.9M | $18.7M | ||
| Q1 25 | $25.0M | $19.0M | ||
| Q4 24 | $-456.0K | $19.6M | ||
| Q3 24 | $-23.5M | $18.2M | ||
| Q2 24 | $-31.2M | $19.0M | ||
| Q1 24 | $-31.7M | $20.8M |
| Q4 25 | — | $107.8M | ||
| Q3 25 | — | $112.5M | ||
| Q2 25 | $175.1M | $105.8M | ||
| Q1 25 | $98.5M | $110.2M | ||
| Q4 24 | $120.5M | $119.4M | ||
| Q3 24 | $139.0M | $121.6M | ||
| Q2 24 | $159.2M | $124.2M | ||
| Q1 24 | $184.7M | $129.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-1.1M |
| Free Cash FlowOCF − Capex | $-15.8M | $-1.5M |
| FCF MarginFCF / Revenue | -84.6% | -5.0% |
| Capex IntensityCapex / Revenue | 0.1% | 1.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-6.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-1.1M | ||
| Q3 25 | — | $-178.0K | ||
| Q2 25 | $-15.8M | $1.1M | ||
| Q1 25 | $-21.0M | $-5.5M | ||
| Q4 24 | $-19.9M | $2.3M | ||
| Q3 24 | $-20.7M | $-4.8M | ||
| Q2 24 | $-19.5M | $6.2M | ||
| Q1 24 | $-26.0M | $-1.7M |
| Q4 25 | — | $-1.5M | ||
| Q3 25 | — | $-390.0K | ||
| Q2 25 | $-15.8M | $941.0K | ||
| Q1 25 | $-21.2M | $-5.5M | ||
| Q4 24 | $-20.0M | $1.9M | ||
| Q3 24 | $-20.7M | $-4.9M | ||
| Q2 24 | $-19.6M | $6.0M | ||
| Q1 24 | $-26.2M | $-2.0M |
| Q4 25 | — | -5.0% | ||
| Q3 25 | — | -1.4% | ||
| Q2 25 | -84.6% | 3.0% | ||
| Q1 25 | -41.6% | -18.8% | ||
| Q4 24 | -52.5% | 5.7% | ||
| Q3 24 | -62.1% | -13.8% | ||
| Q2 24 | -78.2% | 16.8% | ||
| Q1 24 | -63.1% | -5.7% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | 0.1% | 0.5% | ||
| Q1 25 | 0.2% | 0.0% | ||
| Q4 24 | 0.2% | 1.2% | ||
| Q3 24 | 0.1% | 0.4% | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 0.3% | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.34× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | 17.13× | ||
| Q3 24 | -3.61× | -12.21× | ||
| Q2 24 | — | 385.25× | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SYPR
| Sypris Electronics | $17.7M | 59% |
| Transferred At Point In Time | $12.5M | 41% |
